Litoxetine (developmental code names SL 81-0385, IXA-001) is an antidepressant which was under clinical development for the treatment of depression in the early 1990s but was never marketed. It acts as a potent serotonin reuptake inhibitor (Ki for SERT = 7 nM) and modest 5-HT3 receptor antagonist (Ki = 315 nM). It has antiemetic activity, and unlike the selective serotonin reuptake inhibitors (SSRIs), appears to have a negligible incidence of nausea and vomiting. The drug is structurally related to indalpine. Development of litoxetine for depression was apparently ceased in the late 1990s. However, as of March 2017, development of litoxetine has been reinitiated and the drug is now in the phase II stage for the treatment of urinary incontinence.
|Other names||SL 81-0385; IXA-001|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||241.327 g/mol g·mol−1|
|3D model (JSmol)|
- "Litoxetine - AdisInsight". adisinsight.springer.com. Retrieved 2018-08-25.
- Fairweather DB, Patat A, Rosenzweig P, Curson VH, Dunmore C, Dubruc C, Hindmarch I (August 1995). "The psychomotor and cognitive effects of litoxetine in young and middle aged volunteers". British Journal of Clinical Pharmacology. 40 (2): 119–25. doi:10.1111/j.1365-2125.1995.tb05767.x. PMC 1365170. PMID 8562293.
- Zoran Rankovic; Richard Hargreaves; Matilda Bingham (8 October 2012). Drug Discovery for Psychiatric Disorders. Royal Society of Chemistry. pp. 195–. ISBN 978-1-84973-494-3.
- Progress in Drug Research. Birkhäuser. 6 December 2012. pp. 80–. ISBN 978-3-0348-8391-7.
- Angel I, Schoemaker H, Prouteau M, Garreau M, Langer SZ (March 1993). "Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties". European Journal of Pharmacology. 232 (2–3): 139–45. doi:10.1016/0014-2999(93)90767-C. PMID 8385615.